26

Multidrug-resistant pulmonary tuberculosis (MDR-TB) remains a significant global health challenge, particularly in patients with comorbid conditions that complicate diagnosis and treatment. This study investigates the clinical manifestations, microbiological characteristics, and treatment outcomes of MDR-TB in patients with associated diseases. A cohort of 120 patients with confirmed MDR-TB was analyzed, of whom 58 had one or more comorbid conditions, including diabetes mellitus, chronic obstructive pulmonary disease (COPD), HIV infection, and cardiovascular diseases. The study found that comorbidities altered the clinical presentation of MDR-TB, often leading to atypical radiological patterns and prolonged bacterial persistence. Microbiological analysis revealed higher rates of extensive drug resistance and delayed sputum conversion in patients with comorbidities. Treatment outcomes were less favorable in this group, with increased rates of treatment failure and adverse drug reactions. The findings underscore the need for individualized treatment strategies and integrated care approaches for MDR-TB patients with comorbid conditions to improve clinical outcomes

  • Read count 26
  • Date of publication 10-07-2025
  • Main LanguageIngliz
  • Pages137-141
English

Multidrug-resistant pulmonary tuberculosis (MDR-TB) remains a significant global health challenge, particularly in patients with comorbid conditions that complicate diagnosis and treatment. This study investigates the clinical manifestations, microbiological characteristics, and treatment outcomes of MDR-TB in patients with associated diseases. A cohort of 120 patients with confirmed MDR-TB was analyzed, of whom 58 had one or more comorbid conditions, including diabetes mellitus, chronic obstructive pulmonary disease (COPD), HIV infection, and cardiovascular diseases. The study found that comorbidities altered the clinical presentation of MDR-TB, often leading to atypical radiological patterns and prolonged bacterial persistence. Microbiological analysis revealed higher rates of extensive drug resistance and delayed sputum conversion in patients with comorbidities. Treatment outcomes were less favorable in this group, with increased rates of treatment failure and adverse drug reactions. The findings underscore the need for individualized treatment strategies and integrated care approaches for MDR-TB patients with comorbid conditions to improve clinical outcomes

№ Author name position Name of organisation
1 Shamshieva N.N. Department of Infectious Diseases. Tashkent State Medical University
2 Mukhamedov K.S. Children's Infectious Diseases Tashkent State Medical University
3 Kurbanov A.K. ! Tashkent State Medical University
№ Name of reference
1 1.Баласанянц Г.С. Опыт использования бедаквилинав комплексном лечении пациентов с туберкулезом, сочетанным с ВИЧ-инфекцией // Туберкулёз и болезни лёгких. –2017. –Т. 95, No 9. –С. 49-54. https:// doi.org/10.21292/2075-1230-2017-95-9-49-542.Васильева И.А., СтерликовС.А., Тестов В.В., Михайлова Ю.В., Голубев Н.А., Кучерявая Д.А., Гордина А.В., Пономарёв С.Б. Ресурсы и деятель-ность противотуберкулёзных организаций Российской Федерации в 2021–2022 гг. (статистические материалы). М.: РИО ЦНИИОИЗ; 2023. –92 с.3.Васильева И.А., Тестов В.В., Стерликов С.А. Эпидемическая ситуа-ция по туберкулезу в годы пандемии COVID-19 –2020-2021 гг. // Туберкулёз и болезни лёгких. –2022. –Т. 100, No 3. –С. 6-12. https:// doi.org/10.21292/2075-1 230-2022-100-3-6-12 ВИЧ инфекция у взрослых. Клинические рекомендации. Год утвержде-ния 2020. Возрастная категория: взрослые. Год окончания действия: 2022; 114 с.4.ВОЗ. Глобальный отчет по туберкулезу за 2023г. Женева:5.Всемирная организация здравоохранения; 2023г.6.Ставицкая Н.В., Фелькер И.Г., Жукова Е.М., Тлиф А.И., Докторова Н.П., Кудлай Д.А. Многофакторный анализ результатов примене-ния бедаквилина в терапии МЛУ/ШЛУ-туберкулеза легких // Ту-беркулёз и болезни лёгких. –2020. –Т. 98, No 7. –С. 56-62. https:// doi.org/10.21292/2075-1230-2020-98-7-56-627.Федеральный научно-методический центр по профилак-тике и борьбе со СПИДом ФБУН Центрального НИИ эпи-демиологии Роспотребнадзора. URL: https://www.hivrussia. info/wp-content/uploads/2022/03/Spravka-VICH-v-Rossii-na-31.12.2021-g.. pdf[Дата обращения 07.11.2023 г.]8.ЮНЭЙДС. Информационный бюллетень 2023. Глобальная стати-стика по ВИЧ. URL: https://www.unaids.org/sites/defauit/files/media_asset/UNAIDS_FactSheet_ru.pdf [Дата обращения 07.11.2023 г.]9.Bayowa J.R., Kalyango J.N., Baluku J.B., Katuramu R., Ssendikwanawa E., Zalwango J.F., Akunzirwe R., Nanyonga S.M., Amutuhaire J.S., Muganga R.K., Cherop A. Mortality rate and associated factors among patients co-infected with drug resistant tuberculosis/HIV at Mulago National Referral Hospital, Uganda, a retrospective cohort study // PLOS Glob Public Health. –2023. –Vol. 3, No 7. –Р. e0001020. https://doi.org/10.1371/journal.pgph.000102010.Bisson G.P., Bastos M., Campbell J.R., BangD., Brust J.C., Isaakidis P., Lange C., Menzies D., Migliori G.B., Pape J.W., Palmero D., Baghaei P., Tabarsi P., Viiklepp P., Vilbrun S., Walsh J., Marks S.M. Mortality in adults with multidrug-resistant tuberculosis and HIV by antiretroviral therapy andtuberculosis drug use: an individual patient data meta-analysis // Lancet. –2020. –Vol. 396, No 10248. –Р. 402-411. https:// doi.org/10.1016/S0140-6736(20)31316-711.Gandhi N.R., Andrews J.R., Brust J.S., Montreuil R., Weisman D., Heo M., Moll A.P., Friedland G.H., Shah N.S. Riskfactors of mortality among patients with MDR-and XDR-tuberculosis in conditions of high HIV prevalence // International Pulmonary Tuberculosis. –2012. –Vol. 16, No 1. –Р. 90-97. https://doi.org/10.5588/ijted.11.015312.Habimana D.S., Ngabonziza J.S., Migambi P., Muzio-Habimana U., Mutembaiire G., Byukusenge F., Habiambere I., Remera E., Mugwaneza P., Mvikarago I.E., Mazarati J.B., Turate I., Nsanzimana S., Dekru T., de Jong K.B. Predictors of mortality from tuberculosis, resistant torifampicin, among HIV-co-infected patients in Rwanda // Am J Trop Med Hyg. –2021. –Vol. 105, No 1. –Р. 47-53. https://doi.org/10.4269 / ajtmh.20-136113.Oelofse S., Esmail A., Deacon A., Konradi F., Olayanju O., Ngubane N., Howell P., EverittD., Crook A.M., Mendel K.M., Wills G.H., Olugbosi M., Del Parigi A., San E., Calatroni A., Spigelman M., Dheda K. Pretomanid with bedaquiline and linezolid in drug-resistant tuberculosis: comparison of potential cohorts // International Journal of Pulmonary Tuberculosis. –2021. –Vol. 25, No 6. –Р. 453-460. https://doi.org/10.5588/ijtld.21.003514.Wu Wu, Zhang Wu, Wang Wu, Wei J., Wang V, Duan V, Tian Wu, Ren M, Li Z., Wang Wu, Zhang T, Wu N., Huang H. Bedaquiline and Linezolid improve the results of TB treatment in patients with drug-resistant tuberculosis with HIV: a systematic review and meta-analysis // Pharmacol Res. –2022. –No 182. –Р. 106336. https://doi.org/10.1016/ j.phrs.2022.10633615.Yang Q., Han J., Shen J., Peng X., Zhou L., Yin X. Diagnosis and treatment of tuberculosis
Waiting